Top Tech Companies (114)
Don't see your company?
Create a company profile
Founded by MPM Capital, NextPoint Therapeutics has assembled a team of proven drug developers to build a broad strategic pipeline of first-in-class immunotherapies based on a novel, validated checkpoint axis discovered by our scientist founders. Our goal is to deliver new options to people with cancer.
Elemental Machines is helping scientists improve experimental reproducibility and accelerate scientific discovery. With a new suite of connected products that harness the power of cloud-based software, machine learning and distributed sensors, Elemental Machines is giving scientists and researchers an easy, powerful and cost-effective solution fo
BioRAFT designs enterprise level SaaS based software to mitigate risk for laboratory researchers and Environmental Health and Safety (EH&S) professionals. Our management, product development, customer success and sales teams come from academic and pharmaceutical research, scientific software, education, EH&S, healthcare, and aerospace industries.
CELLINK is a global leader in developing and delivering life-science solutions, equipping hundreds of labs and thousands of scientists worldwide with cutting-edge technologies that fuel groundbreaking scientific breakthroughs. With a commitment to quality and innovation, our bioprinters, imaging systems and bioinks have contributed to revolutionary advancements in academic and clinical medicine. We strive to push the limits of what is possible in regenerative medicine and pharmaceutical development, inspiring and empowering collaborators to expand their horizons and overcome any challenge they face. We are striving to enable scientists around the globe that are doing groundbreaking research.
Labviva is the SaaS digital marketplace that connects suppliers, purchasers, and scientists. Our platform seamlessly integrates with your existing procurement systems, to enable purchasing departments to take control of their supply chain by gaining greater visibility of purchasing trends and third-party tail spend, while providing a comprehensive customized marketplace that streamlines the purchasing process with existing workflows. We strive to connect researchers with suppliers of reagents, chemicals, and instrumentation in an intuitive user-friendly platform that supports the priorities of scientists while staying compliant with purchasing rules. Suppliers can easily manage their content of their products. Products are mapped into scientific applications, techniques and protocols, then a relevant a citation index score is generated based on references in peer reviewed journal and related documents and assets are compiled. The results are a unique index of products linked to the relevancy of a product with each scientific use case.
Matterworks is developing advanced AI-powered software and proprietary chemistry reagents to enable real-time, quantitative metabolomics to accelerate the research, development, and manufacturing of biologic therapeutics. Metabolomics measures all the small molecules a cell needs to function. In spite of its far-reaching potential impact across life science disciplines, adoption of metabolomics remains limited and lags behind other ‘omic techniques due to a number of inherent challenges. Matterworks is developing a novel alternative methodology that activates deep learning (DL) for analytical chemistry, to remove the constraints imposed by the requirement for human-interpretable data. Matterworks is on a mission to democratize metabolomics and catalyze its widespread adoption and integration into the life sciences. Our view is very simple: solving metabolomics will advance all of the life sciences industries.
Landmark Bio is a collective endeavor launched by leaders from academia, the life sciences industry, and world-renowned research hospitals to accelerate development and industrialization of next-generation genomic medicine. Inspired by recent advancements in cell and gene therapy, Landmark Bio was established to remove barriers in drug development, create accessible capability, expertise, and solutions, and offer a collaboration platform to advance manufacturing technologies for the new generation of medicines to come. Founding partners include Harvard University, Massachusetts Institute of Technology (MIT), Cytiva, FUJIFILM Diosynth Biotechnologies (FDB), and Alexandria Real Estate Equities, Inc. Other collaborating institutions include Beth Israel Deaconess Medical Center, Boston Children’s Hospital, Mass General Brigham, and the Dana-Farber Cancer Institute. For more information please contact [email protected]
A TARGETED APPROACH TO ACTIVATE CELLULAR CLEARANCE Caraway’s therapeutic approach leverages genetic data and unique biological understanding to develop proprietary small molecules that activate cellular clearance and recycling processes – accelerating clearance of accumulated toxic materials and defective cellular components. New insights in genetics highlight the link between lysosomal function and pathologies in multiple organ systems, including the central nervous system (CNS), heart, kidney, and muscle. Caraway is a leader in targeting these mechanisms with potentially disease-modifying compounds for patients suffering the devastating effects of neurodegenerative and rare diseases including Parkinson’s disease (PD), Amyotrophic Lateral Sclerosis (ALS), and lysosomal storage diseases (LSDs).
